Orbital radiotherapy for Graves' ophthalmopathy

Area of Science:

• Ophthalmology
• Radiation Oncology
• Endocrinology

Background:

• Graves' ophthalmopathy is a severe autoimmune condition affecting the eyes.
• Orbital radiotherapy has been a treatment for this condition for six decades.
• Conventional radiation therapies have been replaced by supervoltage linear accelerators.

Purpose of the Study:

• To review the efficacy and safety of orbital radiotherapy for Graves' ophthalmopathy.
• To identify patient characteristics influencing treatment outcomes.
• To assess the role of orbital radiotherapy in combination with other therapies.

Main Methods:

• Review of established protocols for orbital radiotherapy.
• Analysis of patient selection criteria for optimal outcomes.
• Evaluation of treatment response based on disease activity and duration.
• Assessment of combination therapy with systemic glucocorticoids.

Main Results:

• Orbital radiotherapy demonstrates favorable responses in approximately 60% of cases.
• Active, recent-onset Graves' ophthalmopathy shows better response than longstanding, inactive disease.
• Inflammatory signs, recent eye muscle dysfunction, and optic neuropathy respond well.
• Proptosis and chronic eye muscle restriction show poor response.
• Combination therapy with systemic glucocorticoids yields superior results.

Conclusions:

• Orbital radiotherapy is a well-tolerated and safe treatment for active Graves' ophthalmopathy.
• Careful patient selection is crucial for maximizing treatment success.
• Contraindications include preexisting retinopathy due to risk of further retinal damage.
• No radiation-induced tumors have been reported post-treatment.